Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Acamprosate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acamprosate SCHEMBL6570666 | 0.98 | KDM4E (0.62) | KDM4EMAPK1HIF1APAOXADRA1A | |
| Acamprosate SCHEMBL34472814 | 0.98 | KDM4E (0.62) | KDM4EMAPK1HIF1APAOXADRA1A | |
| Acamprosate SCHEMBL17599929 | 0.98 | KDM4E (0.62) | KDM4EMAPK1HIF1APAOXADRA1A | |
| Acamprosate SCHEMBL347087 | 0.98 | KDM4E (0.62) | KDM4EMAPK1HIF1APAOXADRA1A | |
| Acamprosate SCHEMBL7639758 | 0.98 | KDM4E (0.62) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL17754088 | 0.95 | KDM4E (0.65) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL7402850 | 0.93 | KDM4E (0.70) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL7924796 | 0.91 | KDM4E (0.67) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL7523763 | 0.91 | KDM4E (0.67) | KDM4EMAPK1HIF1APAOXADRA1A | |
| Acamprosate SCHEMBL4051464 | 0.87 | KDM4E (0.50) | KDM4EMAPK1HIF1APAOXADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6118 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE INC (US) | 2026-05-21 | — | — | US | claimed |
| CN-122060012-A | Preparation method of eplerenone and intermediate thereof | 江西百思康瑞药业有限公司 | 2026-05-19 | — | — | CN | claimed |
| EP-4057998-B1 | PROCESS FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION FOR ORAL INTAKE AND DRUG RELEASE IN THE COLON | ETHYPHARM SA (FR) | 2026-05-13 | — | — | EP | claimed |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260108529-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| US-12605367-B2 | Methods of treatment and/or prevention of disorders and symptoms related to BKCa and/or SK channelophathies | Universite de Bordeaux (FR) | 2026-04-21 | — | — | US | claimed |
| EP-4702978-A1 | AGENT FOR TREATING OR PREVENTING AMYOTROPHIC LATERAL SCLEROSIS | Socium Inc. (JP) | 2026-03-04 | — | — | EP | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| US-20260028650-A1 | METHOD TO PRODUCE ALCOHOL AND ALCOHOL PRECURSORS USING GENETICALLY MODIFIED BACTERIA | CHEMICAL EVOLUTION LTD (CA) | 2026-01-29 | — | — | US | claimed |
| WO-2000007583-A2 | TREATMENT OF ADDICTION AND ADDICTION-RELATED BEHAVIOR | BROOKHAVEN SCIENCE ASSOCIATES (US) | 2000-02-17 | — | — | WO | claimed |
| US-6004970-A | Smoking cessation treatments using naltrexone and related compounds | YALE UNIVERSITY (US) | 1999-12-21 | — | — | US | claimed |
| WO-1999048500-A1 | COMBINATION FOR THE TREATMENT OF ALCOHOL AND DRUG DEPENDENCE CONTAINING AN OPIOID ANTAGONIST AND A NMDA RECEPTOR COMPLEX MODULATOR | LIPHA (FR) | 1999-09-30 | — | — | WO | claimed |
| EP-0945133-A1 | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator | LIPHA (FR) | 1999-09-29 | — | — | EP | claimed |
| US-5952389-A | ADMINISTERING AN EFFECTIVE AND NONTOXIC DOSE OF GAMMA-AMINOBUTYRIC ACID RECEPTOR AGONIST SELECTED FROM ACAMPROSATE, CALCIUM N-ACETYLHOMOTAURINE TO TREAT HYPERKINESIA A NERVOUS SYSTEM DISORDER | SYNCHRONEURON (US) | 1999-09-14 | — | — | US | claimed |
| WO-1999037606-A1 | NEW DERIVATIVES OF SULFONIC, PHOSPHONIC AND PHOSPHINIC AMINOALKANE ACIDS, THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | LIPHA (FR) | 1999-07-29 | — | — | WO | claimed |
| WO-1999036064-A2 | METHODS OF TREATING TARDIVE DYSKINESIA AND OTHER MOVEMENT DISORDERS | SYNCHRONEURON, LLC (US) | 1999-07-22 | — | — | WO | claimed |
| EP-0828489-A1 | SMOKING CESSATION TREATMENTS USING NALTREXONE AND RELATED COMPOUNDS | YALE UNIVERSITY (US) | 1998-03-18 | — | — | EP | claimed |
| WO-1997033581-A1 | SMOKING CESSATION TREATMENTS USING NALTREXONE AND RELATED COMPOUNDS | YALE UNIVERSITY (US) | 1997-09-18 | — | — | WO | claimed |
| US-5596095-A | REMOVAL OF NEOPENTYL PROTECTING GROUPS AND REGENERATION OF PARENT DRUGS | PROCEPT, INC. (US) | 1997-01-21 | — | — | US | claimed |